Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.

Choufani EB, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright DG, Seldin DC.

Blood. 2001 Mar 15;97(6):1885-7.

3.

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.

Bone Marrow Transplant. 2001 Oct;28(7):637-42. Review.

4.

High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG.

Ann Intern Med. 2004 Jan 20;140(2):85-93.

PMID:
14734330
5.

Normalization of plasma factor X levels in amyloidosis after plasma exchange.

Beardell FV, Varma M, Martinez J.

Am J Hematol. 1997 Jan;54(1):68-71.

6.

Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.

Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'hara C, Arkin CF, Wright DG, Skinner M.

Blood. 1998 May 15;91(10):3662-70.

7.

[A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].

Adam Z, Matýková M, Krejcí M, Pour L, Kissová J, Slechtová M, Chlupová G, Stavarová Y, Simonides J, Penka M, Mayer J, Hájek R.

Vnitr Lek. 2010 Jan;56(1):67-78. Review. Czech.

PMID:
20184115
8.

Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.

Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller DV, Wright DG, Falk RH, Skinner M.

Blood. 1996 Oct 1;88(7):2801-6.

9.

Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.

Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P, Gisslinger H, Raderer M, Geissler K, Höcker P, Zielinski CC, Oberbauer R, Greinix HT.

Wien Klin Wochenschr. 2006 Feb;118(1-2):49-53.

PMID:
16489526
10.

Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.

Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL, Falk RH, Skinner M.

Ann Intern Med. 2001 May 1;134(9 Pt 1):746-53.

PMID:
11329232
11.

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.

Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.

Br J Haematol. 2004 Dec;127(5):543-51.

PMID:
15566357
12.

Spontaneous major bleeding in acquired factor X deficiency secondary to AL-amyloidosis.

Enjeti AK, Walsh M, Seldon M.

Haemophilia. 2005 Sep;11(5):535-8.

PMID:
16128899
13.

[Therapy options in systemic AL-amyloidosis with renal involvement].

Hetzel GR, Schneider P, Mondry A, Heering P, Heyll A, Grabensee B.

Dtsch Med Wochenschr. 2000 Aug 25;125(34-35):997-1002. German.

PMID:
11004911
14.

Acquired factor X deficiency in light chain amyloidosis: a report of 2 Korean cases.

Ma Y, Kwon EH, Lee JE, Kim K, Kim HJ, Kim SH.

Korean J Lab Med. 2011 Jul;31(3):154-6. doi: 10.3343/kjlm.2011.31.3.154. Epub 2011 Jun 28.

15.

No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement.

Zeier M, Perz J, Linke RP, Donini U, Waldherr R, Andrassy K, Ho AD, Goldschmidt H.

Nephrol Dial Transplant. 2003 Dec;18(12):2644-7.

PMID:
14605290
16.

[AL amyloidosis-associated factor X deficiency].

Croles FN, Beerenhout CH, Mulder AB, Meijer K, Nijziel MR.

Ned Tijdschr Geneeskd. 2014;158(6):A6678. Dutch.

PMID:
24495369
17.

Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.

Matsuda M, Yamada T, Gono T, Shimojima Y, Ishii W, Fushimi T, Sakashita K, Koike K, Ikeda S.

Intern Med. 2005 May;44(5):428-33.

18.

Association of acquired von Willebrand syndrome with AL amyloidosis.

Kos CA, Ward JE, Malek K, Sanchorawala V, Wright DG, O'Hara C, Connors L, Skinner M, Seldin DC.

Am J Hematol. 2007 May;82(5):363-7.

19.

Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.

Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA.

Am J Kidney Dis. 2005 Aug;46(2):270-7. Review.

PMID:
16112045
20.

Four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation.

Reich G, Held T, Siegert W, Kampf D, Dörken B, Maschmeyer G.

Bone Marrow Transplant. 2001 Feb;27(3):341-3.

Supplemental Content

Support Center